FLT3 and acute myeloid leukemia: EFS(SD) at 5 years from study entry for pediatric AML patients which harbored mutant FLT3/ITD was 36.6% (11.6%) compared with 45.6% (5.5%) for the FLT3/ITD wild-type population (P < 0.001; Fig. 1A).